The RAS association domain family protein 1A (RASSF1A) is a tumor suppressor in colorectal cancer (CRC), and is often inactived by hypermethylation. Therefore, we evaluated the association between RASSF1A hypermethylation and the risk and prognosis in CRC. We identified literature through searching PubMed and China National Knowledge Infrastructure databases, and then validated and supplemented the meta-analysis with TCGA analysis. Twenty-three studies involving 2886 subjects of CRC were examined. The meta-analysis showed that RASSF1A promoter methylation inferred high CRC risk (odds ratio, 6.53, 95% confidence interval 3.88-11.01, P < .001) and poor overall survival (hazard ratio 2.85, 95% CI 1.88-4.31, P < .001). The TCGA analysis suggested that effect of RASSF1A promotor methylation was affected by tumor localization (colon vs. rectum). RASSF1A promoter methylation was a predictor of high risk (OR 2.38, 95%CI 1.02-5.6, P = .046) and poor disease free survival(HR 2.25, 95%CI 1.27-3.99, P = .006)in colon adenocarcinoma, but the association was statistically insignificant in rectum adenocarcinoma(HR 1.58, 95% CI 0.69-3.59, P = .28). These results suggested RASSF1A hypermethylation is a risk and a potential prognostic biomarker in CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prp.2020.153009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mutations in tumor suppressor genes Vhl and Rassf1a cause DNA damage, chromosomal instability and induce gene expression changes characteristic of clear cell renal cell carcinoma.
Kidney Int
December 2024
Clinic of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Comprehensive Cancer Center Freiburg (CCCF), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany; Signalling Research Centres BIOSS and CIBSS, Faculty of Biology University of Freiburg, Freiburg, Germany. Electronic address:
RASSF1A is frequently biallelically inactivated in clear cell renal cell carcinoma (ccRCC) due to loss of chromosome 3p and promoter hypermethylation. Here we investigated the cellular and molecular consequences of single and combined deletion of the Rassf1a and Vhl tumor suppressor genes to model the common ccRCC genotype of combined loss of function of RASSF1A and VHL. In mouse embryonic fibroblasts and in primary kidney epithelial cells, double deletion of Rassf1a and Vhl caused chromosomal segregation defects and increased formation of micronuclei, demonstrating that pVHL and RASSF1A function to maintain genomic integrity.
View Article and Find Full Text PDFAberrant promoter methylation, expression and function of RASSF1A gene in a series of Italian parathyroid tumors.
Endocrine
November 2024
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Article Synopsis
- Aberrant epigenetic changes, specifically in DNA methylation and non-coding RNAs, play a significant role in the development of parathyroid tumors, particularly concerning the genes RASSF1A and APC, which are often downregulated in cancers.
- In a study of parathyroid adenomas and carcinomas, RASSF1A promoter methylation was found in approximately 90% of adenomas and was inversely related to tumor size; however, APC methylation appeared less frequently.
- The research concluded that the methylation of RASSF1A and APC is a common feature in parathyroid tumors, with the activity of DNA methyltransferases affecting
Minimally Invasive and Emerging Diagnostic Approaches in Endometrial Cancer: Epigenetic Insights and the Promise of DNA Methylation.
Diagnostics (Basel)
November 2024
Consorzio Sannio Tech, 82030 Apollosa, Italy.
Article Synopsis
- Endometrial cancer (EC) is increasingly common and linked to risk factors like obesity and estrogen exposure, creating a need for non-invasive early diagnosis.
- Recent research highlights the potential of DNA methylation as a biomarker for detecting early-stage EC using minimally invasive samples such as urine and cervical scrapes.
- DNA methylation markers show high diagnostic accuracy, potentially transforming clinical practice by facilitating early detection and personalized treatment plans for endometrial cancer.
Novel strategy for activating gene expression through triplex DNA formation targeting epigenetically suppressed genes.
RSC Chem Biol
August 2024
Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University 1-1-1 Tsushima-naka Kita-ku Okayama 700-8530 Japan
Article Synopsis
- Triplex DNA formation is a promising technique for targeting genes, but has limitations in its original forming sequences.
- Researchers developed a new molecule, guanidino-dN, which effectively recognizes methylated CG base pairs, allowing for enhanced triplex DNA formation.
- This method successfully increased the expression of the RASSF1A gene in breast cancer cells, leading to suppressed cell growth and changes in gene expression related to cancer survival and apoptosis.
Hypermethylation of genes on chromosome 3p as a biomarker for nasopharyngeal carcinoma diagnosis: A Vietnamese case-control study.
Int J Biol Markers
September 2024
Faculty of Biotechnology, Ho Chi Minh City Open University, Ho Chi Minh City, Viet Nam.
Article Synopsis
- The study investigates the role of hypermethylation of tumor suppressor genes located on chromosome 3p in the development of nasopharyngeal carcinoma (NPC), aiming to identify potential diagnostic biomarkers.
- Using biopsy samples and healthy specimens, it was found that a significant percentage of NPC tumors exhibited hypermethylation in several candidate genes, indicating an increased risk of cancer with an association between methylation status and NPC.
- The findings suggest that the methylation of these genes could effectively differentiate nasopharyngeal carcinoma from healthy tissues, particularly in advanced stages, making it a promising tool for diagnosis and monitoring of the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!